Evaluation of FES (16 alpha-[18F]-fluoro-17 beta-estradiol) PET for (re)staging of patients with clinical (locally) advanced or locoregional recurrent estrogen receptor positive breast cancer

R. Iqbal, C. Mo, M. C. F. Cysouw, A. W. J. M. Glaudemans, G. A. P. Hospers, C. P. Schroder, C. C. M. Venema, C. W. Menke-van der Houven van Oordt

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)S88-S88
Number of pages1
JournalEuropean Journal of Cancer
Volume138
Publication statusPublished - Oct-2020
Event12th European Breast Cancer Conference (EBCC) -
Duration: 2-Oct-20203-Oct-2020

Cite this